Robert H. Carnahan

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

The paper identifies a human antibody that neutralizes RSV and hMPV by targeting a novel epitope spanning multiple antigenic sites, showing cross-protection in a mouse model.

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.

This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.

This study shows that ZIKV-117, a neutralizing monoclonal antibody, provides complete protection against ZIKV challenge in rhesus macaques at a low dose.

The paper identifies a pan-betacoronavirus antibody that binds the S2 subunit of spike proteins and induces Fc-dependent antiviral responses, offering insights into non-neutralizing antibody protection.